Vyant Bio Stock Price, News & Analysis (OTCMKTS:VYNT) $0.18 0.00 (0.00%) (As of 12/7/2023 ET) Add Compare Share Share Today's Range$0.17▼$0.1950-Day Range$0.15▼$0.2052-Week Range$0.14▼$1.58Volume1,816 shsAverage Volume168,915 shsMarket Capitalization$1.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort Interest About Vyant Bio Stock (OTCMKTS:VYNT)Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey.Read More VYNT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VYNT Stock News HeadlinesNovember 11, 2023 | finanznachrichten.deVyant Bio, Inc.: Vyant Bio Provides Update on Winddown ActivitiesNovember 10, 2023 | msn.comVyant Bio expects to start liquidation payments in Q4 2024December 8, 2023 | Edge On The Street (Ad)An Unusual Way to Invest in GoldMost financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines. November 10, 2023 | finance.yahoo.comVyant Bio Provides Update on Winddown ActivitiesNovember 1, 2023 | finanznachrichten.deVyant Bio, Inc.: Vyant Bio Announces Stockholder Approval of Plan of DissolutionNovember 1, 2023 | msn.comVyant Bio shareholders approve plan to dissolve companyNovember 1, 2023 | finance.yahoo.comVyant Bio Announces Stockholder Approval of Plan of DissolutionOctober 26, 2023 | finance.yahoo.comLab Notes: Philadelphia health care investment firm closes two funds valued at over $500MDecember 8, 2023 | Edge On The Street (Ad)An Unusual Way to Invest in GoldMost financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines. October 25, 2023 | finanznachrichten.deVyant Bio, Inc.: Vyant Bio Announces Completion of StemoniX Asset SaleOctober 24, 2023 | finance.yahoo.comVyant Bio Announces Completion of StemoniX Asset SaleOctober 19, 2023 | finance.yahoo.comVyant Bio Announces Stockholder Approval of Proposed Asset Sale; 64,110 Votes Needed to Approve Plan of Dissolution; and Adjournment of Special Meeting of StockholdersOctober 11, 2023 | finance.yahoo.comVyant Bio Announces 77,522 Votes Needed to Approve Sale of Assets 175,721 Votes Needed to Approve Winddown of Business Adjournment of Special Meeting of StockholdersSeptember 30, 2023 | finanznachrichten.deVyant Bio, Inc.: Vyant Bio Announces Adjournment of Special Meeting of StockholdersSeptember 20, 2023 | finance.yahoo.comVyant Bio Announces Adjournment of Special Meeting of StockholdersAugust 21, 2023 | yahoo.comMedicare patients took unnecessary genetic cancer tests in man’s $463M scheme, feds sayAugust 21, 2023 | washingtonpost.com‘Asian glow’ from alcohol isn’t just a discomfort. It’s a severe warning.August 18, 2023 | msn.comGene that vastly increases chance of breast cancer found by scientistsAugust 17, 2023 | msn.comThe dangerous gene that vastly increases your chance of breast cancerAugust 9, 2023 | msn.comAI Can Find Cancer’s Origin: StudyJuly 18, 2023 | benzinga.comGenprex – FDA Grants Fast Track Approval For Promising New Cancer Gene TherapyJuly 17, 2023 | bizjournals.comVyant Bio enters into deal to sells its microBrain assets for $2.25MJuly 17, 2023 | finance.yahoo.comAxoSim Enters Into a Definitive Agreement to Acquire Vyant Bio's StemoniX AssetsJuly 6, 2023 | msn.comGene editing helped crack a 100-year-old mystery about cancerJuly 3, 2023 | msn.comCertain genetic mutations linked to treatment-resistant breast cancer, new study discoversJuly 3, 2023 | msn.comTesting begins for Orkney cancer gene linkJune 29, 2023 | usatoday.comAre you truly at risk for prostate cancer? Adding genetics may give more accurate PSA testsSee More Headlines Receive VYNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vyant Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2021Today12/07/2023Next Earnings (Estimated)12/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:VYNT CUSIPN/A CIK1349929 Webstemonix.com Phone(201) 479-1357Fax201-528-9201Employees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,690,000.00 Net Margins-3,474.81% Pretax Margin-3,281.86% Return on Equity-151.82% Return on Assets-97.14% Debt Debt-to-Equity Ratio0.04 Current Ratio2.86 Quick Ratio2.86 Sales & Book Value Annual Sales$666,000.00 Price / Sales1.69 Cash FlowN/A Price / Cash FlowN/A Book Value$1.69 per share Price / Book0.11Miscellaneous Outstanding Shares6,329,000Free Float5,724,000Market Cap$1.12 million OptionableNot Optionable Beta1.68 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Andrew D.C. LaFrence CPA (Age 60)President, CEO & CFO Comp: $407.4kMr. Yung-Ping Yeh M.B.A. (Age 47)M.S., P.M.P., Co-Founder & Director Comp: $22.5kKey CompetitorsZicixOTCMKTS:ZICXAclarionNASDAQ:ACONOpGenNASDAQ:OPGNHemispherx BioPharmaNYSEAMERICAN:HEBAthersysNASDAQ:ATHXView All Competitors VYNT Stock Analysis - Frequently Asked Questions Should I buy or sell Vyant Bio stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vyant Bio in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" VYNT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VYNT, but not buy additional shares or sell existing shares. View VYNT analyst ratings or view top-rated stocks. How have VYNT shares performed in 2023? Vyant Bio's stock was trading at $0.7025 at the start of the year. Since then, VYNT stock has decreased by 74.7% and is now trading at $0.1775. View the best growth stocks for 2023 here. How were Vyant Bio's earnings last quarter? Vyant Bio, Inc. (OTCMKTS:VYNT) released its quarterly earnings data on Thursday, November, 11th. The company reported ($0.75) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.75). The company earned $1.51 million during the quarter, compared to the consensus estimate of $2.19 million. Vyant Bio had a negative net margin of 3,474.81% and a negative trailing twelve-month return on equity of 151.82%. During the same period last year, the company earned ($2.90) EPS. When did Vyant Bio's stock split? Shares of Vyant Bio reverse split on Wednesday, November 2nd 2022. The 1-5 reverse split was announced on Wednesday, November 2nd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 2nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of Vyant Bio? Shares of VYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (OTCMKTS:VYNT) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vyant Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.